GMEDNYSESurgical & Medical Instruments & ApparatusFiscal year ends December 31

GLOBUS MEDICAL INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026

$75.65−1.06 (-1.38%)

Close on Oct 19, 2026

Market cap: $10.39B
P/E (TTM): 19.3
Dividend yield: –

GLOBUS MEDICAL INC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31
Revenue	2,939	2,519	1,568	1,023	958	789	785	713	636	564	545	474	434	386	331	288
Cost of Revenue	958	1,035	548	264	239	217	180	159	150	135	132	111	100	75	69	54
Gross Profit	1,981	1,484	1,020	759	719	572	605	554	486	429	412	364	334	311	263	234
Research & Development	147	164	124	73	97	85	60	55	44	45	36	31	27	28	23	21
Selling, General & Admin	1,178	981	644	432	408	355	355	312	268	222	210	189	183	169	140	123
Advertising Expenses	–	–	–	–	–	0.60	1.10	1.90	1.50	0.90	0.40	0.50	0.50	0.40	0.40	0.30
Operating Expenses	–	–	887	531	547	460	433	384	324	275	240	225	232	196	165	147
Operating Income	480	166	133	228	172	111	172	169	162	154	172	138	102	115	97	88
Other Non-Operating Income	125	-45	32	15	8.45	14	18	19	8.09	3.14	0.58	0.28	0.33	-0.14	-0.41	0.05
Merger & Restructuring Charges	15	24	0	–	–	–	–	–	–	–	–	–	–	–	–	–
Asset Impairment Charges	0	0	0	0	0	0	0	0	0.50	–	–	–	–	–	–	–
Gain (Loss) on Sale of Assets	-13	-5.55	-1.54	-0.30	-0.46	-0.81	-0.87	3.56	0	0	–	–	–	–	–	–
Legal Settlements	–	-0.31	-0.43	-2.34	-5.92	-0.01	-2.19	-5.88	-2.67	–	7.60	–	–	0.79	-1.47	-2.79
Pretax Income	605	121	165	243	180	126	190	189	170	157	173	139	102	115	97	88
Income Tax Expense	67	18	43	53	31	24	35	32	63	53	60	46	33	41	36	33
Net Income	538	103	123	190	149	102	155	156	107	104	113	92	69	74	61	54
Net Income to Common	538	103	123	190	149	–	–	–	–	–	–	–	–	74	61	54
EPS (Basic)(per share)	3.98	0.76	1.09	1.89	1.48	1.04	1.57	1.60	1.12	1.09	1.19	0.98	0.74	0.82	0.69	0.61
EPS (Diluted)(per share)	3.92	0.75	1.07	1.85	1.44	1.01	1.52	1.54	1.10	1.08	1.17	0.97	0.73	0.80	0.67	0.60
Shares Outstanding (Basic, Weighted)(shares)	135	136	113	100	101	99	99	98	96	96	95	94	93	90	88	89
Shares Outstanding (Diluted, Weighted)(shares)	137	138	115	103	104	101	102	101	98	96	96	95	94	92	90	91
EBITDA	757	419	279	296	242	174	225	211	204	193	196	160	121	133	114	103
Net Interest Income	–	-4.19	20	14	9.30	14	17	13	6.61	3.06	1.30	0.81	0.47	0.08	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 68.5%
Operating margin: 20.3%
Net margin: 17.0%
Return on equity, FY2025: 12.3%

Financial strength

Current ratio: 4.62
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 105.9%

Valuation

P/E ratio: 19.3
Price to sales: 3.30
Price to book: 2.18
Dividend yield: –